Supported by extensive genetic studies of the RAS signal transduction pathway in Drosophila, its high degree of evolutionary conservation, and its strategic position as the most downstream signaling gatekeeper in the oncogenic K-RAS signaling pathway, SIAH is uniquely positioned to become the next generation anti-K-RAS drug target in pancreatic cancer (Figure 1 and Figure 2B). This evidence concerns the gene KRAS and pancreatic neoplasm.